|
|
Exelixis Inc (NASDAQ: EXEL) |
|
Price: $56.7800
$-0.12 
-0.211%
|
| Day's High:
| $57.779998779296875
| Week Perf:
| -1.13 %
|
| Day's Low: |
$ 56.33 |
30 Day Perf: |
8.52 % |
| Volume (M): |
1,879,628 |
52 Wk High: |
$ 59.72 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$46.54 |
| Open: |
$57.04 |
52 Wk Low: |
$33.76 |
|
|
| Market Capitalization (Millions $) |
14,744 |
| Shares
Outstanding (Millions) |
260 |
| Employees |
1,147 |
| Revenues (TTM) (Millions $) |
2,436 |
| Net Income (TTM) (Millions $) |
1,896 |
| Cash Flow (TTM) (Millions $) |
62 |
| Capital Exp. (TTM) (Millions $) |
11 |
Business Description
Exelixis Inc.
is a biopharmaceutical company headquartered in Alameda, California, United States.
The company was founded in 1994, and it develops and commercializes proprietary therapeutics for the treatment of cancer and other serious diseases.
Exelixis has a diverse pipeline of small molecule therapeutics that are designed to address various types of cancer.
Its lead product, cabozantinib, is an inhibitor of multiple tyrosine kinases, including MET, VEGF receptors, AXL, RET, and ROS1.
Cabozantinib targets cancer cells in multiple ways and has demonstrated significant clinical benefits across several indications, including renal cell carcinoma, hepatocellular carcinoma, and advanced prostate cancer.
Apart from cabozantinib, Exelixis also has several other product candidates in its pipeline, including XL092, which is currently in Phase 1 clinical trials for the treatment of solid tumors, and XL102, which is being developed for the treatment of hematologic malignancies.
Exelixis has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Roche, and Merck.
These collaborations are aimed at advancing the development and commercialization of its small molecule therapeutics in various markets around the world.
Overall, Exelixis is a leading player in the field of cancer therapeutics, with a strong focus on innovation, research, and development.
The company is committed to improving the lives of patients with cancer and other serious diseases, and it is well-positioned to continue its growth trajectory in the coming years.
Company Address: 1851 Harbor Bay Parkway Alameda, 94502 CA
Company Phone Number: 837-7000 Stock Exchange / Ticker: NASDAQ EXEL
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Oct 20 2025 8:27 AM UTC
Exelixis, Inc. (Nasdaq: EXEL) has announced the results of a subgroup analysis from the CABINET phase 3 pivotal trial evaluating the efficacy of CABOMETYX (cabozantinib) against a placebo in patients with advanced neuroendocrine tumors (NET) originating in the lungs and thymus. The findings are scheduled to be presented during the Monday Poster Session: Neuroendocrine Tumour...
|
| Business Update
Published Wed, Mar 26 2025 5:39 PM UTC
In a significant advancement in cancer treatment, Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for patients aged 12 years and older with previously treated advanced neuroendocrine tumors (NET). This approval marks a notable milestone in the management of well-differentiated pancreatic neuroendocrine tumor...
|
| Business Update
Published Mon, Feb 17 2025 2:38 PM UTC
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) recently made a significant impact in the oncology community with new findings from the CheckMate -9ER trial, evaluating the efficacy of CABOMETYX (cabozantinib) in combination with Opdivo (nivolumab) for patients with previously untreated advanced renal cell carcinoma (RCC). Presented at the American Society of Clinical Oncolo...
|
| Business Update
Published Mon, Feb 17 2025 10:53 AM UTC
In an exciting development in the treatment of advanced renal cell carcinoma (RCC), Exelixis, Inc. (Nasdaq: EXEL) has announced the compelling five-year follow-up results from the phase 3 CheckMate -9ER trial. Presented at the ASCO GU 2025 conference in Alameda, California, these results highlight the sustained efficacy benefits of CABOMETYX (cabozantinib) in combination wit...
|
| Business Update
Published Sat, Jan 25 2025 8:51 AM UTC
The biotechnology firm Exelixis, Inc. (Nasdaq: EXEL), based in Alameda, California, has made significant strides in both clinical and legal domains. Recently, the company revealed promising results from a subgroup analysis of its Phase 3 CABINET pivotal study. This study focused on the efficacy of Cabozantinib in treating advanced gastrointestinal neuroendocrine tumors (GI-N...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
3.17 $ |
| Revenues (TTM) |
9.38 $
|
| Cash Flow (TTM) |
0.24 $ |
| Cash |
3.23 $
|
| Book Value |
7.1 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
2,123,731 |
| Net
Income per Employee (TTM) |
1,653,085 |
| Receivable Turnover Ratio (TTM) |
7.81 |
| Inventory Turnover Ratio (TTM) |
3.28 |
| Asset Turnover Ratio (TTM) |
0.9 |
|
|
| Per Share |
|
| Earnings (TTM) |
3.17 $
|
| Revenues (TTM) |
9.38 $ |
| Cash Flow (TTM) |
0.24 $ |
| Cash |
3.23 $
|
| Book Value |
7.1 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product |
|
 179.42 % |
of total Revenue |
| Collaboration |
|
17.74 % |
of total Revenue |
| Reportable |
|
197.16 % |
of total Revenue |
| Product, Gross |
|
255.79 % |
of total Revenue |
| Product, Sales Discounts and Allowances |
|
-76.37 % |
of total Revenue |
| License |
|
1.64 % |
of total Revenue |
| Collaboration services revenues Collaborative arrangement with Takeda |
|
0.52 % |
of total Revenue |
| United States |
|
180.84 % |
of total Revenue |
| Europe |
|
13.61 % |
of total Revenue |
| Japan |
|
2.71 % |
of total Revenue |
| CABOMETYX |
|
178.69 % |
of total Revenue |
| COMETRIQ |
|
0.73 % |
of total Revenue |
| |
On January 13 2025 the Exelixis Inc provided following guidance
nnExelixis, Inc. Issues Preliminary Results for Fiscal Year 2024, Offers Outlook for 2025, and Highlights Strategic Priorities and Goals for the Upcoming Yearnn
nnALAMEDA, Calif.nn — Exelixis, Inc. (Nasdaq: EXEL) has released its preliminary unaudited financial results for the fiscal year 2024 and provided guidance for the upcoming fiscal year 2025, alongside a comprehensive update on its strategic business initiatives. The company is gearing up for a pivotal 2025, marked by significant clinical and regulatory advancements, particularly within its cabozantinib portfolio.
While specific financial projections for 2025 remain undisclosed, Exelixis emphasizes its commitment to driving growt...
|
|
|
1.39%